Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV232 single ascending dose in healthy Chinese volunteers
NCT06070857Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Oct 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing LV232 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 7 days, Maximum Plasma Concentration at 48 hours and 11 more. Started Oct 2023; status: completed.
02
Drugs
LV232
Beyond the preview
Go deeper on NCT06070857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070857.